Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

CNBC

A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China

EconomyDaily Composite
ShareXFacebook

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

C

Source

CNBC

Read full article at CNBC

Opens original article in a new tab

Advertisement

Related Economy Stories

Advertisement